Free Trial
OTCMKTS:MDGEF

Medigene (MDGEF) Stock Price, News & Analysis

→ The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad)
Free MDGEF Stock Alerts
$2.43
-0.33 (-11.96%)
(As of 03/28/2024)
Compare
Today's Range
$2.43
▼
$2.43
50-Day Range
$1.50
▼
$2.76
52-Week Range
$1.50
▼
$2.84
Volume
500 shs
Average Volume
600 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartShort Interest

About Medigene

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

MDGEF Stock Price History

MDGEF Stock News Headlines

May 14, 2024 | globenewswire.com
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
May 12, 2024 | americanbankingnews.com
Short Interest in Medigene AG (OTCMKTS:MDGEF) Drops By 33.8%
May 2, 2024 | globenewswire.com
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
April 26, 2024 | globenewswire.com
Medigene AG reports Financial Results and Business Update for Q1 2024
April 4, 2024 | globenewswire.com
Medigene AG Secures European Patent for its iM-TCR Technology
March 28, 2024 | globenewswire.com
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
March 19, 2024 | globenewswire.com
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 18, 2024 | globenewswire.com
Medigene AG to report full year 2023 financial results on March 28, 2024
March 4, 2024 | globenewswire.com
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
See More Headlines
Receive MDGEF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:MDGEF
CUSIP
N/A
CIK
N/A
Web
www.medigene.com
Phone
(989) 200-0330
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Selwyn Ho MB BS (Age 53)
    MBBS, CEO & Member of Executive Management Board
    Comp: $409.36k
  • Dr. Dolores J. Schendel
    Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development
  • Dr. Ernst-Ludwig Winnacker (Age 83)
    Co-Founder & Chairman Scientific Advisory Board
    Comp: $21.3k
  • Dr. Birger Kohlert
    Chief Financial Officer
  • Pamela Keck
    Vice President of Investor Relations & Corporate Communications
  • Dr. Kirsty Crame M.D.
    VP and Head of Clinical Research & Development

Key Competitors

View All Competitors

MDGEF Stock Analysis - Frequently Asked Questions

How have MDGEF shares performed in 2024?

Medigene's stock was trading at $1.50 at the beginning of 2024. Since then, MDGEF stock has increased by 62.0% and is now trading at $2.43.
View the best growth stocks for 2024 here.

Are investors shorting Medigene?

Medigene saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 9,200 shares, a decrease of 33.8% from the April 15th total of 13,900 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
View Medigene's Short Interest.

How do I buy shares of Medigene?

Shares of MDGEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MDGEF) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club